Prevalence, prognosis, and health care resource utilization in carriers of pathogenic germline variants in BRCA1/2 with incident early-stage breast cancer: a Finnish population-based study
DOI:
https://doi.org/10.2340/1651-226X.2024.40829Keywords:
BRCA, genetics, health care resource utilization, hereditary breast cancer, prevalence, survivalAbstract
Background and purpose: Data on real-world prevalence and outcomes in patients diagnosed with pathogenic germline variants in BRCA1 or BRCA2 (gBRCAm) breast cancer is sparse.
Material and methods: An observational cohort study including all patients diagnosed with incident early-stage breast cancer and recorded in Helsinki University Hospital data lake 2012–2022, accounting for one-third of the Finnish breast cancer patient population.
Results: Among 14,696 incident early-stage breast cancer patients, 11.2% (n = 1,644) were tested for gBRCAm. Of the tested population, 7.4% (n = 122) carried gBRCAm. Of the 122 gBRCAm patients, 95.1% (n = 116) were women, with a median age at diagnosis of 46.4 years. Among the same patient group, HER2 status was available for 87.7% (n = 107) of the patients. Among these, 49.5% (n = 53) had hormone receptor-positive (HR+), HER2-negative breast cancer, 13.1% were (n = 14) HER2-positive, and 37.3% (n = 40) of patients had triple-negative breast cancer. The tested patients were significantly younger compared with non-tested patients. No significant differences in overall survival or healthcare resource utilization between the tested patients with gBRCAm and gBRCA wild-type (gBRCAwt) were observed.
Interpretation: This comprehensive observational study supports previous findings of gBRCAm prevalence in the Western early-stage breast cancer population. While no differences in survival were observed between patients with gBRCAm and gBRCAwt, it is important to consider the potential influence of selection bias, particularly due to the younger gBRCAm testing target population and the overall low frequency of testing. Therefore, a substantial proportion of the patients carrying gBRCAm likely remained undiagnosed, and wider screening criteria are warranted.
Downloads
References
Breast Cancer Association Consortium, Dorling L, Carvalho S, Allen J, González-Neira A, Luccarini C, et al. Breast cancer risk genes – Association analysis in more than 113,000 women. N Engl J Med. 2021;384:428–39.
https://doi.org/10.1056/NEJMoa1913948 DOI: https://doi.org/10.1056/NEJMoa1913948
Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105:812–22.
https://doi.org/10.1093/jnci/djt095 DOI: https://doi.org/10.1093/jnci/djt095
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5:77–106.
https://doi.org/10.1016/j.gendis.2018.05.001 DOI: https://doi.org/10.1016/j.gendis.2018.05.001
Tschernichovsky R, Goodman A. Risk-reducing strategies for ovarian cancer in BRCA mutation carriers: a balancing act. Oncologist. 2017;22:450–9.
https://doi.org/10.1634/theoncologist.2016-0444 DOI: https://doi.org/10.1634/theoncologist.2016-0444
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–75.
https://doi.org/10.1001/jama.2010.1237 DOI: https://doi.org/10.1001/jama.2010.1237
Robson M, Im S-A, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–33.
https://doi.org/10.1056/NEJMoa1706450 DOI: https://doi.org/10.1056/NEJMoa1706450
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–63.
https://doi.org/10.1056/NEJMoa1802905 DOI: https://doi.org/10.1056/NEJMoa1802905
Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al. Adjuvant Olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384:2394–405.
https://doi.org/10.1056/NEJMoa2105215 DOI: https://doi.org/10.1056/NEJMoa2105215
Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO clinical practice guideline. Ann Oncol. 2023;34:33–47.
https://doi.org/10.1016/j.annonc.2022.10.004 DOI: https://doi.org/10.1016/j.annonc.2022.10.004
Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, et al. Germline testing in patients with breast cancer: ASCO-Society of surgical oncology guideline. J Clin Oncol. 2024;42:584–604.
https://doi.org/10.1200/JCO.23.02225 DOI: https://doi.org/10.1200/JCO.23.02225
Kurian AW, Bedrosian I, Kohlmann WK, Somerfield MR, Robson ME. Germline testing in patients with breast cancer: ASCO-society of surgical oncology guideline Q and A. JCO Oncol Pract. 2024;20:OP2300771.
https://doi.org/10.1200/OP.23.00771 DOI: https://doi.org/10.1200/OP.23.00771
Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol. 2018;19:169–80.
https://doi.org/10.1016/S1470-2045(17)30891-4 DOI: https://doi.org/10.1016/S1470-2045(17)30891-4
Vocka M, Zimovjanova M, Bielcikova Z, Tesarova P, Petruzelka L, Mateju M, et al. Estrogen receptor status oppositely modifies breast cancer prognosis in BRCA1/BRCA2 mutation carriers versus non-carriers. Cancers (Basel). 2019;11:738.
https://doi.org/10.3390/cancers11060738 DOI: https://doi.org/10.3390/cancers11060738
Huzarski T, Byrski T, Gronwald J, Górski B, Domagala P, Cybulski C, et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol. 2013;31:3191–6.
https://doi.org/10.1200/JCO.2012.45.3571 DOI: https://doi.org/10.1200/JCO.2012.45.3571
Zhu Y, Wu J, Zhang C, Sun S, Zhang J, Liu W, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis. Oncotarget. 2016;7:70113–27.
https://doi.org/10.18632/oncotarget.12158 DOI: https://doi.org/10.18632/oncotarget.12158
Huszno J, Kołosza Z, Grzybowska E. BRCA1 mutation in breast cancer patients: Analysis of prognostic factors and survival. Oncol Lett. 2019;17:1986–95.
https://doi.org/10.3892/ol.2018.9770 DOI: https://doi.org/10.3892/ol.2018.9770
Mäklin S, Kokko P. Terveyden-ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2017. Finnish Institute for Health and Welfare , Helsinki, 2017.
Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500–24.
https://doi.org/10.1016/j.ijsu.2014.07.014 DOI: https://doi.org/10.1016/j.ijsu.2014.07.014
Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543–61.
https://doi.org/10.2147/CLEP.S206949 DOI: https://doi.org/10.2147/CLEP.S206949
Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, et al. A study of over 35,000 women with breast cancer tested with a 25‐gene panel of hereditary cancer genes. Cancer. 2017;123:1721–30.
https://doi.org/10.1002/cncr.30498 DOI: https://doi.org/10.1002/cncr.30498
Kurian AW, Ward KC, Howlader N, Deapen D, Hamilton AS, Mariotto A, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. JCO. 2019;37:1305–15.
https://doi.org/10.1200/JCO.18.01854 DOI: https://doi.org/10.1200/JCO.18.01854
Nilsson MP, Winter C, Kristoffersson U, Rehn M, Larsson C, Saal LH, et al. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Fam Cancer. 2017;16:187–93.
https://doi.org/10.1007/s10689-016-9953-x DOI: https://doi.org/10.1007/s10689-016-9953-x
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34:1460–8.
https://doi.org/10.1200/JCO.2015.65.0747 DOI: https://doi.org/10.1200/JCO.2015.65.0747
González-Rivera M, Lobo M, López-Tarruella S, Jerez Y, Del Monte-Millán M, Massarrah T, et al. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Res Treat. 2016;156:507–15.
https://doi.org/10.1007/s10549-016-3792-1 DOI: https://doi.org/10.1007/s10549-016-3792-1
Nilsson MP, Hartman L, Idvall I, Kristoffersson U, Johannsson OT, Loman N. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status. Breast Cancer Res Treat. 2014;144:133–42.
https://doi.org/10.1007/s10549-014-2842-9 DOI: https://doi.org/10.1007/s10549-014-2842-9
Wagner TM, Möslinger RA, Muhr D, Langbauer G, Hirtenlehner K, Concin H, et al. BRCA1-related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer. 1998;77:354–60. DOI: https://doi.org/10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.3.CO;2-A
https://doi.org/10.1002/(sici)1097-0215(19980729)77:3<354::aid-ijc8>3.0.co;2-n DOI: https://doi.org/10.1002/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N
Sun L, Cui B, Wei X, Sadique Z, Yang L, Manchanda R, et al. Cost-effectiveness of genetic testing for all women diagnosed with breast cancer in China. Cancers (Basel). 2022;14:1839.
https://doi.org/10.3390/cancers14071839 DOI: https://doi.org/10.3390/cancers14071839
Lourenção M, Simões Correa Galendi J, Galvão H de CR, Antoniazzi AP, Grasel RS, Carvalho AL, et al. Cost-effectiveness of BRCA 1/2 genetic test and preventive strategies: using real-world data from an upper-middle income country. Front Oncol. 2022;12:951310.
https://doi.org/10.3389/fonc.2022.951310 DOI: https://doi.org/10.3389/fonc.2022.951310
Oh M, McBride A, Bhattacharjee S, Slack M, Jeter J, Abraham I. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Rev Pharmacoecon Outcomes Res. 2023;23:309–16.
https://doi.org/10.1080/14737167.2023.2169135 DOI: https://doi.org/10.1080/14737167.2023.2169135
Wu H-L, Luo Z-Y, He Z-L, Gong Y, Mo M, Ming W-K, et al. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. Br J Cancer. 2023;128:638–46.
https://doi.org/10.1038/s41416-022-02111-y DOI: https://doi.org/10.1038/s41416-022-02111-y
Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292:1317–25.
https://doi.org/10.1001/jama.292.11.1317 DOI: https://doi.org/10.1001/jama.292.11.1317
Haiderali A, Rhodes WC, Gautam S, Huang M, Sieluk J, Skinner KE, et al. Healthcare resource utilization and cost among patients treated for early-stage triple-negative breast cancer. Future Oncol. 2021;17:3833–41.
https://doi.org/10.2217/fon-2021-0531 DOI: https://doi.org/10.2217/fon-2021-0531
Suomen Rintasyöpäryhmä. Rintasyövän valtakunnallinen diagnostiikka-ja hoitosuositus 2024. [Accessed 24th September 2024]National diagnostic and treatment guidelines for breast cancer. Finnish Breast Cancer Group; 2024. Available from https://rintasyoparyhma.yhdistysavain.fi/hoitosuositus/
Phillips KA. Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol. 2000;18:107S–12S.
Additional Files
Published
How to Cite
License
Copyright (c) 2023 Peeter Karihtala, Outi Laatikainen, Samuli Tuominen, Trude Ågesen, Rasmus Eliasen
This work is licensed under a Creative Commons Attribution 4.0 International License.
